Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hematology

Relapsed and refractory PTCL—into the therapeutic abyss

Nature Reviews Clinical Oncology volume 8, pages 321–322 (2011)Cite this article

Subjects

Outcomes in patients with peripheral T-cell lymphomas are poor and there are no established standards of care for patients in the relapsed and refractory setting, owing in part to the lack of multicenter, controlled clinical trials. Recently, encouraging results were reported in this setting with pralatrexate—a novel folate analog.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Vose, J. et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 26, 4124–4130 (2008).

    Article  Google Scholar 

  2. Schmitz, N. et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116, 3418–3425 (2010).

    Article  CAS  Google Scholar 

  3. Delmer, A. et al. A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05–01T trial [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a8554 (2009).

    Google Scholar 

  4. Reimer, P. et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J. Clin. Oncol. 27 106–113 (2009).

    Article  CAS  Google Scholar 

  5. Rodríguez, J. et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann. Oncol. 18, 652–657 (2007).

    Article  Google Scholar 

  6. D'Amore, F. et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLs)—overall and subtype-specific results of a phase II study from the Nordic Lymphoma Group. Haematologica 94 (Suppl. 2), a437 (2009).

    Google Scholar 

  7. O'Connor, O. A. et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J. Clin. Oncol. 29, 1182–1189 (2011).

    Article  CAS  PubMed Central  Google Scholar 

  8. O'Connor, O. A. et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J. Clin. Oncol. 27, 4357–4364 (2009).

    Article  CAS  PubMed Central  Google Scholar 

  9. Piekarz, R. L. et al. Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood doi:10.1182/blood-2010-10-312603.

    Article  CAS  PubMed Central  Google Scholar 

  10. Coiffier, B. et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy [abstract]. Blood 116, a114 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale University School of Medicine, 333 Cedar Street, New Haven, 06510, CT, USA

    Francine Foss

Authors
  1. Francine Foss
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

F. Foss is a consultant for and receives honoraria from Allos, Celgene and Eisai. She is a consultant for and receives research support from Merck and she receives honoraria from Cephalon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Foss, F. Relapsed and refractory PTCL—into the therapeutic abyss. Nat Rev Clin Oncol 8, 321–322 (2011). https://doi.org/10.1038/nrclinonc.2011.51

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.51

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing